

DATE: December 16, 2025

QIP POLICY LETTER 25-006

TO: ALL QUALITY INCENTIVE POOL (QIP) ENTITIES

SUBJECT: CALENDAR YEAR (CY) 2025 REPORTING UPDATE TO THE EIGHT (8) TRENDING BREAK MEASURES

PURPOSE:

This QIP Policy Letter (QPL) informs QIP entities of a reporting update to the eight (8) trending break measures for CY2025, i.e.: Q-AIS-E, Q-CMS138, Q-EED, Q-FUM, Q-QPP118, Q-QPP6, Q-WCV, and Q-W30.

BACKGROUND:

The QIP program is authorized by the Welfare and Institutions Code section 14197.4(c). On January 15, 2025, the Centers for Medicare and Medicaid Services (CMS) approved the one-year QIP preprints for the Designated Public Hospitals (DPHs) and District and Municipal Public Hospitals (DMPHs) for CY2025.

POLICY:

For CY2025, QIP entities must re-report baseline data (CY2024 data, using the CY2025 measure specifications) in the ***"Trending Break Data for CY2024 Reported in CY2025"*** field in the QIP Reporting Application for the eight (8) measures listed below. QIP entities should use the most current sources of data available when re-calculating the CY2024 baselines, using the CY2025 measure specifications.

- i. Q-AIS-E: Adult Immunization Status (AIS-E)
- ii. Q-CMS138: *Tobacco Use: Screening and Cessation Intervention
- iii. Q-EED: Eye Exam for Patients With Diabetes (EED)
- iv. Q-FUM: *Follow-Up After Emergency Department Visit for Mental Illness (FUM)¹
- v. Q-QPP118: Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF ≤40%)
- vi. Q-QPP6: Coronary Artery Disease (CAD): Antiplatelet Therapy
- vii. Q-WCV: *Child and Adolescent Well-Care Visits (WCV)
- viii. Q-W30: *Well-Child Visits in the First 30 Months of Life (W30)

*Note: * indicates a Priority Measure*

¹ If QIP entities choose to report the MCP-produced rate as P4P for Q-FUM, they must also report MCP's baseline data.

Please contact your QIP liaison or email the QIP Mailbox at qip@dhcs.ca.gov if there are any questions concerning this QPL.

Sincerely,

Palav Babaria, MD, MHS

Deputy Director & Chief Quality Officer
Quality and Population Health Management
California Department of Health Care Services